Arriello originally created the app for use by pharmaceutical reps and clinicians in the field. Because case intake data can be captured immediately using natural speech in the local languages of trial participants, IntelliCASE removes the need for intermediate processing via a third party – adding to its efficiency and cost-effectiveness.
Commenting on the selection of IntelliCASE, Rob Curtis, Chief Marketing Officer at Arriello said: “The app is completely intuitive and convenient to use, removing any practical or logistical barriers to Adverse Event reporting. The data can be captured naturally, in the moment – without the need for an intermediary, and requiring minimal exertion.
“Crucially, IntelliCASE is a fully validated system which can be implemented rapidly. With this powerful, targeted app, Arriello offers an easy to use pharmacovigilance system that’s proved readily adaptable.”